INTRODUCTION: Neurofilament (Nf) aggregates are a common pathological feature of neurodegenerative disorders. Although Nf levels have been investigated as a potential disease biomarker, Nf aggregates may mask Nf epitopes, preventing accurate quantification by immunoassay. Using the SOD1(G93A) mouse model of amyotrophic lateral sclerosis, we developed a method to disrupt Nf aggregates, allowing optimal immunoassay performance. METHODS: Phosphorylated (NfH(SMI35)) and hyperphosphorylated (NfH(SMI34)) Nf levels in plasma from 120-day SOD1(G93A) mice were quantified using an in-house ELISA modified for use with small volumes. Different pre-analytical methods were tested for their ability to solubilize Nf aggregates and immunoblotting was used for qualitative analysis. RESULTS: A 'hook effect' was observed for serially diluted plasma samples quantified using an ELISA originally developed for CSF samples. Immunoblotting confirmed the existence of high molecular-weight NfH aggregates in plasma and the resolving effect of timed urea on these aggregates. Thermostatic (pre-thawing) and chemical (calcium chelators, urea) pre-analytical processing of samples had variable success in disrupting NfH aggregates. Timed urea-calcium chelator incubation yielded the most consistent plasma NfH levels. A one hour sample pre-incubation with 0.5M urea in Barbitone-EDTA buffer at room temperature resolved the "hook effect" without compromising the ELISA. In SOD1(G93A) mice, median levels of NfH(SMI34) were over 10-fold and NfH(SMI35) levels 5-fold greater than controls. CONCLUSION: NfH aggregates can be solubilised and the "hook effect" abolished by a one-hour sample pre-incubation in a urea-calcium chelator-enriched buffer. This method is applicable for quantification of NfH phosphoforms in experimental and disease settings where Nf aggregate formation occurs.
INTRODUCTION: Neurofilament (Nf) aggregates are a common pathological feature of neurodegenerative disorders. Although Nf levels have been investigated as a potential disease biomarker, Nf aggregates may mask Nf epitopes, preventing accurate quantification by immunoassay. Using the SOD1(G93A) mouse model of amyotrophic lateral sclerosis, we developed a method to disrupt Nf aggregates, allowing optimal immunoassay performance. METHODS: Phosphorylated (NfH(SMI35)) and hyperphosphorylated (NfH(SMI34)) Nf levels in plasma from 120-day SOD1(G93A) mice were quantified using an in-house ELISA modified for use with small volumes. Different pre-analytical methods were tested for their ability to solubilize Nf aggregates and immunoblotting was used for qualitative analysis. RESULTS: A 'hook effect' was observed for serially diluted plasma samples quantified using an ELISA originally developed for CSF samples. Immunoblotting confirmed the existence of high molecular-weight NfH aggregates in plasma and the resolving effect of timed urea on these aggregates. Thermostatic (pre-thawing) and chemical (calcium chelators, urea) pre-analytical processing of samples had variable success in disrupting NfH aggregates. Timed urea-calcium chelator incubation yielded the most consistent plasma NfH levels. A one hour sample pre-incubation with 0.5M urea in Barbitone-EDTA buffer at room temperature resolved the "hook effect" without compromising the ELISA. In SOD1(G93A) mice, median levels of NfH(SMI34) were over 10-fold and NfH(SMI35) levels 5-fold greater than controls. CONCLUSION:NfH aggregates can be solubilised and the "hook effect" abolished by a one-hour sample pre-incubation in a urea-calcium chelator-enriched buffer. This method is applicable for quantification of NfH phosphoforms in experimental and disease settings where Nf aggregate formation occurs.
Authors: Axel Petzold; Ching-Hua Lu; Mike Groves; Johan Gobom; Henrik Zetterberg; Gerry Shaw; Sonia O'Connor Journal: J R Soc Interface Date: 2020-01-08 Impact factor: 4.118
Authors: Rocco Adiutori; Fabiola Puentes; Michael Bremang; Vittoria Lombardi; Irene Zubiri; Emanuela Leoni; Johan Aarum; Denise Sheer; Simon McArthur; Ian Pike; Andrea Malaspina Journal: Brain Commun Date: 2021-07-09
Authors: Ching-Hua Lu; Axel Petzold; Bernadett Kalmar; James Dick; Andrea Malaspina; Linda Greensmith Journal: PLoS One Date: 2012-07-16 Impact factor: 3.240
Authors: Ching-Hua Lu; Corrie Macdonald-Wallis; Elizabeth Gray; Neil Pearce; Axel Petzold; Niklas Norgren; Gavin Giovannoni; Pietro Fratta; Katie Sidle; Mark Fish; Richard Orrell; Robin Howard; Kevin Talbot; Linda Greensmith; Jens Kuhle; Martin R Turner; Andrea Malaspina Journal: Neurology Date: 2015-05-01 Impact factor: 9.910
Authors: M Khalil; C Enzinger; C Langkammer; S Ropele; A Mader; A Trentini; M L G Vane; M Wallner-Blazek; G Bachmaier; J-J Archelos; M J A Koel-Simmelink; M A Blankenstein; S Fuchs; F Fazekas; C E Teunissen Journal: Mult Scler Date: 2012-08-23 Impact factor: 6.312
Authors: Ching-Hua Lu; Axel Petzold; Jo Topping; Kezia Allen; Corrie Macdonald-Wallis; Jan Clarke; Neil Pearce; Jens Kuhle; Gavin Giovannoni; Pietro Fratta; Katie Sidle; Mark Fish; Richard Orrell; Robin Howard; Linda Greensmith; Andrea Malaspina Journal: J Neurol Neurosurg Psychiatry Date: 2014-07-09 Impact factor: 10.154